GMP for Cannabis – what you need to know

GMP for Cannabis – what you need to know

Hamburg, Germany

Course No 17583



Please contact us and we will inform you accordingly:

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail:


Jennifer Ayotte,  AI Data Grow, USA
Claudia Baumung, CVUA Karlsruhe, Germany
Oliver el-Atma, CVUA Karlsruhe, Germany
Dr Reinhard Kerker, GMP Inspectorate, Germany
Dr Andrea Kühn-Hebecker, Concept Heidelberg, Germany, ECA Cannabis Working Group
Silja du Mont,  GDP/GCP Inspectorate, Germany 
Luis Meirinhos Soares, GMP / GACP Inspector, Infarmed, Portugal
Dr Ingrid Walther, Pharma Consulting Walther, Germany, Leader of the ECA Cannabis Working Group
Stephanie Wilmott,  Consultant, Canada; ECA Cannabis Working Group


Medical cannabis has been permitted for prescription in Germany since 2017, causing a need for producers supplying pharmacists and physicians with the newly legalized drug. In addition, more and more countries around the world are following Germany by introducing programs in order to legalize cannabis for medical use. But what qualifies as medical grade cannabis? And which aspects have to be considered for CBD-Products? This conference will give you an overview of all relevant regulatory and GACP/GMP/GDP requirements and aspects for medical cannabis and CBD-Products.


In March 2017, the national German legislature expanded the options for prescribing medical cannabis products by passing a law amending provisions under the Narcotics Law and other regulations. These products, however, must comply with the relevant requirements laid down under Medicinal and Narcotics Law, including GACP/ GMP and GDP. Therefore, the BfArM (the Federal Institute for Drugs and Medical Devices) has taken over new responsibilities by establishing the Cannabis Agency. This agency is meant to help in ensuring supplies for medical-quality Cannabis.

Unlike AGES in Austria, though, where cultivation of medical cannabis has already been established, cannabis will not be cultivated by BfArM itself, but by commissioned companies. Cannabis is not meant to be stored directly at BfArM during any stage of the purchasing, harvesting or distribution process. These steps will be carried out by relevant producers or other commissioned companies (i.e. suppliers, importers). Hence, the agency will manage and monitor the cultivation, harvest, processing, quality assurance, storage, packaging and distribution of cannabis to wholesalers, chemists or manufacturers.

The GMP inspectorates are responsible for issuing manufacturing and import licenses or GMP Certificates. Thus, they will perform inspections at the sites of manufacturers who apply for these certificates and licenses.

In summary:
  • The Cannabis Agency is responsible for ensuring that only medical grade cannabis is supplied,
  • The relevant requirements based on the underlying legal framework (including Pharmacopoeias) and the corresponding GMP, GDP and GACP guidelines must be complied with, and finally
  • Cannabis for medical purposes is also subject to the provisions of the Narcotics Law.
Non-EU suppliers, who currently produce according to GPP, will have to implement EU-GMP standards if they want to supply medical cannabis to the EU market. However, since there is currently no harmonized EU standard and pharmacopoeial monograph for medical cannabis (and extracts), national legislations, guidelines and pharmacopoeial monographs will have to be followed and applied in addition t

Target Group

This conference addresses specific GMP aspects to consider for Growers, Manufacturers, Start-Ups, Suppliers, Importers, QPs and QA/QC personnel involved in Cannabis production and release. The topics provided are also of interest for GACP/GMP/GDP Inspectors responsible for issuing a GMP certificate or manufacturers/import license.


Welcome and Introduction
  •  GMP for Cannabis: setting the scene
GMP Certification / Manufacturing and Importation Authorization
  •  Aspects to consider for applications for Manufacturing and Importation Authorizations
  •  Aspects to consider for analytical labs
  •  GMP certification: What you need to know
  •  Inspections in Europe and beyond: Typical and recurrent compliance issues
GDP for Cannabis
  •  Requirements for transport to pharmacies, veterinary dispensaries, hospitals
  •  Requirements for distribution of cannabis through international distribution partners, wholesalers and 3PL partners
Aspects to consider for CBD (and other Hemp) Products
  • Requirements due to the German Narcotics Law
  • How to differentiate between CBD/Cannabis Products for medical use and other CBD (Hemp) Products?
  • Which legal rules apply?
  • Practical examples
Overview of Pharmacopoeial Monographs
  •  Europe (Ph. Eur.)
  •  Germany (DAB / DAC)
  •  Denmark
  •  Netherlands
  •  Switzerland (Ph. Helv.)
  •  Israel
  •  New Zealand (Product Quality Standards Monograph)
  •  USA (USP)
The intersection between GACP and GMP - View on the Inspection of Cannabis GACP and its relation to GMP
  • When does GACP end and (EU) GMP start?
  • What will be checked during GACP and EU GMP inspections?
  • Observations in inspections
  • Open questions and issues to be solved
  •  Differences and similarities
  •  Validation as part of the PQS
  •  Stability testing / stability programme
  •  QP Batch Release
How to get GMP certified for Export?
  •  Growing, harvest, packaging, quality control and release: Requirements to fulfil
  •  Agreements & Responsibilities
  •  EU GMP Conformity & Export / Import License
Experiences - Lessons learned
  •  Application of GMP principles to Cannabis
  •  Quality management System (QMS) including Qualification/Validation
  •  DAB Monograph “Cannabis Flos”: Points to consider

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information